Literature DB >> 8157017

Surfactant replacement therapy: a new risk factor in developing retinopathy of prematurity?

J U Termote1, N E Schalij-Delfos, D Wittebol-Post, H A Brouwers, B R Hoogervorst, B P Cats.   

Abstract

We documented the prevalence of retinopathy of prematurity (ROP) in a group of 46 infants suffering from a moderate or severe respiratory distress syndrome and treated with surfactant replacement therapy (SRT) and 61 controls admitted in the year prior to the institution of SRT. Mortality in the treatment group was lower than in the control group (15.5% versus 23.8; P = 0.29). The ROP prevalence in the treatment group was 47.8% and in the control group 27.9%. To analyse the contribution of SRT alone to the prevalence of ROP, multivariate analysis using logistic regression technique was used. The odds ratio for SRT was 5.2 with a 95% confidence interval of 1.3-20.7, P = 0.02. The prevalence of severe ROP in the surfactant treated group was not increased compared to the control group. From our data we conclude that SRT increases the risk of developing ROP but is not associated with more severe forms of ROP.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8157017     DOI: 10.1007/bf01959221

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  21 in total

1.  Surfactant replacement therapy and the prevalence of acute retinopathy of prematurity.

Authors:  T R Tubman; S J Rankin; H L Halliday; S S Johnston
Journal:  Biol Neonate       Date:  1992

2.  Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: final analysis of a multicenter, double-blind, randomized trial and comparison with similar trials. The Surfactant-TA Study Group.

Authors:  T Fujiwara; M Konishi; S Chida; K Okuyama; Y Ogawa; Y Takeuchi; H Nishida; H Kito; M Fujimura; H Nakamura
Journal:  Pediatrics       Date:  1990-11       Impact factor: 7.124

3.  Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. American Exosurf Pediatric Study Group 1.

Authors:  A Corbet; R Bucciarelli; S Goldman; M Mammel; D Wold; W Long
Journal:  J Pediatr       Date:  1991-02       Impact factor: 4.406

4.  Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Collaborative European Multicenter Study Group.

Authors: 
Journal:  Pediatrics       Date:  1988-11       Impact factor: 7.124

5.  Calf lung surfactant extract prophylaxis and retinopathy of prematurity.

Authors:  M X Repka; M L Hudak; C F Parsa; J M Tielsch
Journal:  Ophthalmology       Date:  1992-04       Impact factor: 12.079

6.  Timely incidence of retinopathy of prematurity and its consequences for the screening strategy.

Authors:  K E Tan; B P Cats
Journal:  Am J Perinatol       Date:  1989-07       Impact factor: 1.862

7.  An international classification of retinopathy of prematurity. II. The classification of retinal detachment. The International Committee for the Classification of the Late Stages of Retinopathy of Prematurity.

Authors: 
Journal:  Arch Ophthalmol       Date:  1987-07

8.  Vitamin E and retrolental fibroplasia: ultrastructural support of clinical efficacy.

Authors:  F L Kretzer; H M Hittner; A T Johnson; R S Mehta; L B Godio
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

9.  Vitamin E supplementation and the retinopathy of prematurity.

Authors:  L Johnson; D Schaffer; G Quinn; D Goldstein; M J Mathis; C Otis; T R Boggs
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

10.  Vitamin E protects against retinopathy of prematurity through action on spindle cells.

Authors:  F L Kretzer; R S Mehta; A T Johnson; D G Hunter; E S Brown; H M Hittner
Journal:  Nature       Date:  1984 Jun 28-Jul 4       Impact factor: 49.962

View more
  3 in total

Review 1.  Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.

Authors:  Kay D Beharry; Gloria B Valencia; Douglas R Lazzaro; Jacob V Aranda
Journal:  Semin Perinatol       Date:  2016-01-29       Impact factor: 3.300

2.  Retinopathy of prematurity in a controlled trial of prophylactic surfactant treatment.

Authors:  P M Pennefather; W Tin; M P Clarke; S Fritz; N P Strong
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

Review 3.  Retinopathy of prematurity: a review of risk factors and their clinical significance.

Authors:  Sang Jin Kim; Alexander D Port; Ryan Swan; J Peter Campbell; R V Paul Chan; Michael F Chiang
Journal:  Surv Ophthalmol       Date:  2018-04-19       Impact factor: 6.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.